Author(s): Carol Moreno, John C. Byrd, Peter Hillmen, et. al. Abstract: S 769 Session topic: 6. Chronic lymphocytic leukemia and related disorders – Clinical Background: Ibrutinib is a first-in-class, once-daily oral inhibitor of Bruton’s tyrosine kinase. Ibrutinib as a single agent is indicated by the EMEA and US FDA for the treatment...
Pro zobrazení tohoto obsahu je třeba být přihlášen.